Financial Comparison: ImmunityBio (NASDAQ:IBRX) and eXoZymes (NASDAQ:EXOZ)

ImmunityBio (NASDAQ:IBRX) and eXoZymes (NASDAQ:EXOZ) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Insider and Institutional Ownership

8.6% of ImmunityBio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 58.0% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ImmunityBio and eXoZymes, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1	0	6	0	2.71
eXoZymes	1	1	0	0	1.50

ImmunityBio currently has a consensus target price of $16.00, suggesting a potential upside of 82.44%. Given ImmunityBio’s stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than eXoZymes.

Volatility and Risk

ImmunityBio has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, eXoZymes has a beta of 3.19, indicating that its stock price is 219% more volatile than the S&P 500.

Profitability

This table compares ImmunityBio and eXoZymes’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
eXoZymes	N/A	-292.15%	-158.66%

Valuation & Earnings

This table compares ImmunityBio and eXoZymes”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29 million	82.04	-$351.40 million	($0.97)	-9.04
eXoZymes	N/A	N/A	-$9.16 million	($1.19)	-3.46

eXoZymes has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Summary

ImmunityBio beats eXoZymes on 9 of the 13 factors compared between the two stocks.

About ImmunityBio

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

About eXoZymes

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.